VBI Vaccines has launched the PreHevbri [hepatitis B vaccine (recombinant, adsorbed)] for adults in the UK.
The vaccine is intended for active immunisation against all known hepatitis B virus (HBV) subtypes in adults.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PreHevbri is marketed in the UK through the existing commercial infrastructure and distribution networks of Valneva as part of a marketing and distribution agreement signed in September 2022.
The vaccine is also anticipated to prevent hepatitis D, which cannot develop without a hepatitis B infection.
VBI president and CEO Jeff Baxter stated: “We are delighted to announce the availability of PreHevbri in the UK, marking the first European market launch of our 3-antigen hepatitis B vaccine, which builds upon the increasing momentum for use in the US.
“We believe Valneva’s local commercial capabilities and relationships will be of significant value not only in this initial European launch, but also in the additional European markets where PreHevbri is expected to launch over the next several months.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPreHevbri includes three hepatitis B surface antigens of the virus – S, pre-S1 and pre-S2.
The vaccine also secured approval in the US, Canada, Israel and the European Union/European Economic Area.
It is marketed as PreHevbrio in the US and Canada and as Sci-B-Vac in Israel.
Hepatitis B is a major infectious disease with over 290 million people infected across the world.
